Biocytogen Pharmaceutical - Public Comps and Valuation Multiples

Biocytogen Pharmaceutical Overview

About Biocytogen Pharmaceutical

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Founded

2009

HQ

Employees

1.1K+

Website

biocytogen.com.cn

Sectors

Drug Development & Therapeutics

Financials

Last FY Revenue $139M

Last FY EBITDA $43.1M

EV

$2.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Biocytogen Pharmaceutical Financials

See Biocytogen Pharmaceutical valuation multiples based on analyst estimates

Biocytogen Pharmaceutical P&L

In the most recent fiscal year, Biocytogen Pharmaceutical reported revenue of $139M and EBITDA of $43.1M.

Biocytogen Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Biocytogen Pharmaceutical valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$139M	XXX	XXX	XXX
Gross Profit	XXX	$108M	XXX	XXX	XXX
Gross Margin	XXX	78%	XXX	XXX	XXX
EBITDA	XXX	$43.1M	XXX	XXX	XXX
EBITDA Margin	XXX	31%	XXX	XXX	XXX
EBIT	XXX	$19.3M	XXX	XXX	XXX
EBIT Margin	XXX	14%	XXX	XXX	XXX
Net Profit	XXX	$4.8M	XXX	XXX	XXX
Net Margin	XXX	3%	XXX	XXX	XXX
Net Debt	XXX	$2.9M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Biocytogen Pharmaceutical including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Biocytogen Pharmaceutical achieved $139M in revenue and $43.1M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$139M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$108M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	77.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$43.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	31.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$19.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	13.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$4.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	3.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$2.9M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Biocytogen Pharmaceutical

This financial data table provides comprehensive performance metrics for Biocytogen Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Biocytogen Pharmaceutical reported $139M in total revenue.
Fiscal year EBITDA was $43.1M.
The company maintained a gross profit margin of 77.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.0%.
Net profit margin reached 3.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Biocytogen Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Biocytogen Pharmaceutical Stock Performance

Biocytogen Pharmaceutical has current market cap of CNY 19.4B (or $2.8B), and EV of CNY 19.6B (or $2.8B).

Market Cap Evolution

Biocytogen Pharmaceutical Stock Data

As of December 17, 2025, Biocytogen Pharmaceutical's stock price is CNY 44 (or $6).

See Biocytogen Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.8B	$2.8B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Biocytogen Pharmaceutical Valuation Multiples

Biocytogen Pharmaceutical's trades at 20.0x EV/Revenue multiple, and 64.4x EV/EBITDA.

See valuation multiples for Biocytogen Pharmaceutical and 15K+ public comps

Biocytogen Pharmaceutical Financial Valuation Multiples

As of December 17, 2025, Biocytogen Pharmaceutical has market cap of $2.8B and EV of $2.8B.

Equity research analysts estimate Biocytogen Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biocytogen Pharmaceutical's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	20.0x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	64.4x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	143.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	578.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	112.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Biocytogen Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Biocytogen Pharmaceutical Margins & Growth Rates

Biocytogen Pharmaceutical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Biocytogen Pharmaceutical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biocytogen Pharmaceutical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Biocytogen Pharmaceutical and other 15K+ public comps

Biocytogen Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	31%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	33%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	64%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial